<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TUSSIGON- hydrocodone bitartrate and homatropine methylbromide tablet </strong><br>Pfizer Laboratories Div Pfizer Inc<br></p></div>
<h1>TUSSIGON<span class="Sup">®</span> Tablets <br>(Hydrocodone bitartrate and homatropine methylbromide)<br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b0fdb11b-294b-4ba2-acb5-d15a7e03ceaa"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">CII</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_06e15a78-8223-41a5-96bf-cc0a253d2c8e"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Tussigon contains hydrocodone (dihydrocodeinone) bitartrate, a semi-synthetic centrally-acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage.</p>
<p>Each TUSSIGON tablet contains: Hydrocodone Bitartrate USP 5 mg Homatropine Methylbromide USP 1.5 mg.</p>
<p>The hydrocodone component is 4,5α- Epoxy-3-methoxy-17-methylmorphinan -6-one-tartrate (1:1) hydrate (2:5), a fine white crystal or crystalline powder which is derived from the opium alkaloid, thebaine, has a molecular weight of (494.50) and may be represented by the following structural formula:</p>
<div class="Figure"><img alt="ChemStructure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c0bba34-07db-42f5-9e5e-ad79b71b4276&amp;name=tussigon-01.jpg"></div>
<p>C<span class="Sub">18</span>H<span class="Sub">21</span>N0<span class="Sub">3</span> • C<span class="Sub">4</span>H<span class="Sub">6</span>0<span class="Sub">6</span> • 2½H<span class="Sub">2</span>0</p>
<p>Hydrocodone Bitartrate</p>
<p>Homatropine methylbromide is 8- Azoniabicyclo[3.2.1]octane, 3-[(hydroxy phenylacetyl)oxy]-8, 8-dimethyl-,bromide, endo-, a white crystal or fine white crystalline powder, with a molecular weight of (370.29).</p>
<div class="Figure"><img alt="ChemStructure2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c0bba34-07db-42f5-9e5e-ad79b71b4276&amp;name=tussigon-02.jpg"></div>
<p>C<span class="Sub">17</span>H<span class="Sub">24</span>BrN0<span class="Sub">3</span></p>
<p>Homatropine Methylbromide</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_884521ca-c4f7-4368-b780-3d42556e56a4"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> center. In excessive doses, hydrocodone like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, physical and psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>Following a 10 mg oral dose of hydrocodone administered to five adult male subjects, the mean peak concentration was 23.6 ± 5.2 ng/ml. Maximum serum levels were achieved at 1.3± 0.3 hours and the half-life was determined to be 3.8 ± 0.3 hours. Hydrocodone exhibits a complex pattern of metabolism including 0-demethylation, N-demethylation and 6-keto reduction to the corresponding 6-α and 6-β-hydroxymetabolites.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_472c46cf-3e04-4a9a-b7de-6cf75309d4bc"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">TUSSIGON is indicated for the symptomatic relief of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_7befdc2b-07fb-4823-8887-ebf172117926"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">TUSSIGON should not be administered to patients who are hypersensitive to hydrocodone or homatropine methylbromide.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_01c94058-2328-428a-946a-3a06389c5c24"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Hydrocodone can produce <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">drug dependence</span> of the morphine type and, therefore, has the potential for being abused. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated administration of TUSSIGON and it should be prescribed and administered with the same degree of caution appropriate to the use of other narcotic drugs (SEE <span class="Bold"><a href="#i4i_abuse_dependence_id_28f4e050-b04c-48a8-a93a-1cdbd0b2a4b8">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_bc46e723-a099-4210-b45f-41a5f01007bb"></a><a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</h2>
<p class="First">TUSSIGON produces dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by directly acting on brain stem respiratory centers. If <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0283f45e-4780-4912-b4da-8cc90183bf7c"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> And <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span>:</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> properties of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions which may obscure the clinical course of patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1b53970b-3c65-43ca-9019-36fd33b0277b"></a><a name="section-6.3"></a><p></p>
<h2>Acute Abdominal Conditions:</h2>
<p class="First">The administration of TUSSIGON or other narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_39e37427-57bf-4902-8ab6-08ddf809741b"></a><a name="section-6.4"></a><p></p>
<h2>Pediatric Use:</h2>
<p class="First">In young children, as well as adults, the respiratory center is sensitive to the depressant action of narcotic <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> suppressants in a dose-dependent manner. Benefit to risk ratio should be carefully considered especially in children with respiratory embarrassment (e.g. <span class="product-label-link" type="condition" conceptid="260134" conceptname="Croup">croup</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_565846a9-f434-41dd-87ae-edb47e28cb6e"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_cc8022d5-54fb-4508-b629-82b44b92ce69"></a><a name="section-7.1"></a><p></p>
<h2>General:</h2>
<p class="First">Before prescribing medication to suppress or modify <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, it is important to ascertain that the underlying cause of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> is identified, that modification of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> does not increase the risk of clinical or physiological complications, and that appropriate therapy for the primary disease is provided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fce2ab4d-235c-4ba3-8032-a352d76522c3"></a><a name="section-7.2"></a><p></p>
<h2>Special Risk Patients:</h2>
<p class="First">TUSSIGON should be given with caution to certain patients such as the elderly or debilitated, and those with severe impairment of hepatic or renal functions, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison's disease, <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span> or <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_97a6a0a3-0f75-4d51-ad4c-d45e3c5f013d"></a><a name="section-7.3"></a><p></p>
<h2>Information for Patients:</h2>
<p class="First">Hydrocodone may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using TUSSIGON should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_aba8c964-ffd0-4951-ac54-496feb437189"></a><a name="section-7.4"></a><p></p>
<h2>Drug Interactions:</h2>
<p class="First">Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents or other CNS depressants (including alcohol) concomitantly with TUSSIGON may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
<p>The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressants or hydrocodone.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_23467b85-cd53-4040-a81e-cc21975e4e50"></a><a name="section-7.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Studies of TUSSIGON in animals to evaluate the carcinogenic and mutagenic potential and the effect on fertility have not been conducted.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_0eb18975-5b50-4615-874a-df3c4d8c358f"></a><a name="section-7.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_c58c67a9-b5c4-4620-8259-f6590c136b19"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Italics">Teratogenic Effects</span></h3>
<p class="First">Pregnancy Category C: Animal reproduction studies have not been conducted with TUSSIGON. It is also not known whether TUSSIGON can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. TUSSIGON should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="i4i_non_teratogenic_id_dede6150-e040-4b24-8f53-46d0f95067e3"></a><a name="section-7.6.2"></a><p></p>
<h3><span class="Italics">Nonteratogenic Effects</span></h3>
<p class="First">Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and excessive <span class="product-label-link" type="condition" conceptid="4136768" conceptname="Crying">crying</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactive</span> reflexes, increased <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, increased stools, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_e285e111-d246-43f5-a149-d778a30ae96c"></a><a name="section-7.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">As with all narcotics, administration of TUSSIGON to the mother shortly before delivery may result in some degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the newborn, especially if higher doses are used.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_4bea1f33-77b5-4a1d-944d-b7e9eb483656"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from TUSSIGON, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_78de0164-70eb-4b1c-b086-32f99471bd7f"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness of TUSSIGON in children under six have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_234c5f6c-7ecf-4161-bf98-7e973ebb13a8"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_bc9f7689-3f98-46ac-84a4-cae73342a037"></a><a name="section-8.1"></a><p></p>
<h2>Central Nervous System:</h2>
<p class="First">Sedation, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, mental clouding, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, impairment of mental and physical performance, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4029621" conceptname="Fear">fear</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood changes</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8c058edb-c9d0-4b32-87ba-61ea1edda231"></a><a name="section-8.2"></a><p></p>
<h2>Gastrointestinal System:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur; they are more frequent in ambulatory than in recumbent patients. Prolonged administration of TUSSIGON may produce <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6dbb0a01-18b7-47b5-b6f9-62d8731d31ce"></a><a name="section-8.3"></a><p></p>
<h2>Genitourinary System:</h2>
<p class="First">Ureteral spasm, spasm of <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> sphincters and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> have been reported with opiates.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db389a66-3dad-4e14-abdf-71cb531ea741"></a><a name="section-8.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span>:</h2>
<p class="First">TUSSIGON may produce dose-related <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> by acting directly on brain stem respiratory centers (see <span class="Bold"><a href="#i4i_overdosage_id_d4311385-613f-4686-8338-f9c9f3cca877">OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4019cd36-d1aa-4624-a47f-28991d8475b6"></a><a name="section-8.5"></a><p></p>
<h2>Dermatological:</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_id_28f4e050-b04c-48a8-a93a-1cdbd0b2a4b8"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">TUSSIGON is a Schedule II narcotic. Psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance may develop upon repeated administration of narcotics; therefore, TUSSIGON should be prescribed and administered with caution. However, psychic <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is unlikely to develop when TUSSIGON is used for a short time for the treatment of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assume clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> may develop after a few days of narcotic therapy.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d4311385-613f-4686-8338-f9c9f3cca877"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_042e06d6-affd-43d6-9526-c7e8265976c1"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms:</h2>
<p class="First">Serious overdosage with hydrocodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur. The ingestion of very large amounts of TUSSIGON may, in addition, result in acute homatropine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6063b98f-d037-4bfb-8ee8-3aceddf491e4"></a><a name="section-10.2"></a><p></p>
<h2>Treatment:</h2>
<p class="First">Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_abb86fa7-bdf4-4c43-8e95-8d728899ec61"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93a4f56d-48a1-401d-bcd9-ec638887cbfa"></a><a name="section-11.1"></a><p></p>
<h2>Adult:</h2>
<p class="First">One (1) tablet every 4 to 6 hours as needed; do not exceed six (6) tablets in 24 hours.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c266bdca-8bdc-41c8-8079-6497db05bca0"></a><a name="section-11.2"></a><p></p>
<h2>Children 6 to 12 years of age:</h2>
<p class="First">One-half (1/2) tablet every 4 to 6 hours as needed; do not exceed three (3) tablets in 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_1ba7017c-b930-4b9d-88e7-ce817cd07afc"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each blue, scored tablet contains 5 mg hydrocodone bitartrate and 1.5 mg homatropine methylbromide and is available in:</p>
<p>Bottles of 100 NDC 61570-102-01 </p>
<p>Store at controlled room temperature 15°–30°C (59°–86°F). Oral prescription where permitted by state law. </p>
<p>This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com. </p>
<p><img alt="logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c0bba34-07db-42f5-9e5e-ad79b71b4276&amp;name=tussigon-03.jpg"></p>
<p>LAB-0732-1.0<br>September 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_f0da4db3-7994-4f50-af4e-27978f93a7de"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label</h1>
<p class="First">NDC 61570-102-01</p>
<p><span class="Bold">Tussigon</span><span class="Sup">®</span><br> (hydrocodone bitartrate and<br> homatropine methylbromide)<br><span class="Bold">CII</span></p>
<p><span class="Bold">5 mg/1.5 mg</span></p>
<p>EACH TABLET CONTAINS:<br> Hydrocodone bitartrate 5 mg<br> Homatropine methylbromide 1.5 mg</p>
<p>100 TABLETS</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6c0bba34-07db-42f5-9e5e-ad79b71b4276&amp;name=tussigon-04.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TUSSIGON 		
					</strong><br><span class="contentTableReg">hydrocodone bitartrate and homatropine methylbromide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:61570-102</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCODONE BITARTRATE</strong> (HYDROCODONE) </td>
<td class="formItem">HYDROCODONE BITARTRATE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HOMATROPINE METHYLBROMIDE</strong> (METHYLHOMATROPINE) </td>
<td class="formItem">HOMATROPINE METHYLBROMIDE</td>
<td class="formItem">1.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DP;082;Tussigon</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:61570-102-01</td>
<td class="formItem">100  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA088508</td>
<td class="formItem">07/30/1985</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pfizer Laboratories Div Pfizer Inc
							(134489525)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1248fd87-debd-484b-8da8-37ab64bce670</div>
<div>Set id: 6c0bba34-07db-42f5-9e5e-ad79b71b4276</div>
<div>Version: 1</div>
<div>Effective Time: 20141006</div>
</div>
</div> <div class="DistributorName">Pfizer Laboratories Div Pfizer Inc</div></p>
</body></html>
